The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers.
作者信息
Liu Michelle, Roden Dan M, Peterson Josh F
机构信息
Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
出版信息
Clin Pharmacol Ther. 2021 Oct;110(4):860-862. doi: 10.1002/cpt.2215. Epub 2021 Mar 10.
DOI:10.1002/cpt.2215
PMID:33690885
Abstract
摘要
相似文献
1
The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers.扩大氯吡格雷FDA黑框警告至CYP2C19中间代谢者的理由。
Clin Pharmacol Ther. 2021 Oct;110(4):860-862. doi: 10.1002/cpt.2215. Epub 2021 Mar 10.
2
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.CYP2C19*17 等位基因对经皮冠状动脉介入治疗后接受基于基因型的抗血小板治疗患者结局的影响。
Clin Pharmacol Ther. 2021 Mar;109(3):705-715. doi: 10.1002/cpt.2039. Epub 2020 Oct 2.
3
[Who should receive clopidogrel after stroke?].中风后谁应该接受氯吡格雷治疗？
Tidsskr Nor Laegeforen. 2018 May 28;138(9). doi: 10.4045/tidsskr.18.0277. Print 2018 May 29.
4
Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.CYP2C19基因多态性对估算肾小球滤过率（eGFR）降低的轻度卒中或短暂性脑缺血发作（TIA）患者双重抗血小板治疗预后的影响：CHANCE研究的亚组分析
Pharmacogenomics J. 2018 Dec;18(6):713-720. doi: 10.1038/s41397-018-0018-4. Epub 2018 Mar 8.
5
Clopidogrel Pharmacogenetics.氯吡格雷药物遗传学。
Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. doi: 10.1161/CIRCINTERVENTIONS.119.007811.
6
Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.CYP2C19 基因指导的抗血小板治疗与急性冠状动脉综合征患者普遍使用抗血小板药物的经济学评价：系统评价。
J Cardiovasc Pharmacol Ther. 2020 May;25(3):201-211. doi: 10.1177/1074248420902298. Epub 2020 Feb 6.
7
Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后使用基于基因型的抗血小板治疗的临床结果和可持续性。
Circ Genom Precis Med. 2018 Apr;11(4):e002069. doi: 10.1161/CIRCGEN.117.002069.
8
Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.CYP2C19基因多态性对血小板对氯吡格雷反应的影响以及对颈动脉支架置入术中高剂量与标准剂量氯吡格雷疗效的影响。
Eur J Vasc Endovasc Surg. 2016 Feb;51(2):175-86. doi: 10.1016/j.ejvs.2015.09.020. Epub 2015 Oct 31.
9
Clopidogrel: what is a cardiologist to do?氯吡格雷：心脏病专家该怎么做？
J Clin Pharmacol. 2014 Aug;54(8):881-3. doi: 10.1002/jcph.330.
10
CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.CYP2C19基因分型是伊拉克经皮冠状动脉介入治疗后服用氯吡格雷患者不良心血管结局的独立预测因素。
J Cardiovasc Pharmacol. 2018 Jun;71(6):347-351. doi: 10.1097/FJC.0000000000000577.
引用本文的文献
1
Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.基于网络药理学分析 CYP2C19 基因特性对颈动脉支架置入术后氯吡格雷抗血小板聚集的影响。
BMC Pharmacol Toxicol. 2024 Jun 6;25(1):34. doi: 10.1186/s40360-024-00750-w.
2
Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine.转化药物基因组学：种族意识医学的发现、证据综合与应用
Clin Pharmacol Ther. 2021 Oct;110(4):909-925. doi: 10.1002/cpt.2357. Epub 2021 Jul 29.
Zotero 插件